Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 34 of 58, showing 10 Applications out of 576 total, starting on record 331, ending on 340

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

331.

ECCT/20/06/05   SEVUSMART Trial
    SEVUSMART TRIAL   Sevuparin as a potential adjunctive therapy in children with severe malaria   
Principal Investigator(s)
1. Kathryn Maitland Maitland
Site(s) in Kenya
Kilifi County Hospital
 
08-08-2021 View

332.

ECCT/20/06/02   EMPACTA Covid19 Study
    A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
AgaKhan University Hospital Nairobi
 
09-07-2020 View

333.

ECCT/20/06/09   HIV-CORE 006
    A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa   
Principal Investigator(s)
1. Professor Walter Jaoko, Jaoko,
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. KEMRI/ Wellcome Trust Research Programme (Kilifi county)
 
09-09-2020 View

334.

ECCT/20/09/05   THE ELLAVI UBT STUDY
    An investigation into the barriers and facilitators of scaling up the innovative, low-cost Ellavi Uterine Balloon Tamponade for postpartum hemorrhage in Kenya       
Principal Investigator(s)
1. Zahida P Qureshi
2. Omondi Ogutu
3. Alfred Onyango Osoti
4. George Nyakundi Gwako
5. James Soki
6. James Gitonga
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Mbagathi Hospital (Nairobi City county)
3. St. Marys Mission Hospital (Nairobi City county)
 
02-12-2020 View

335.

ECCT/20/07/03   STAND
    A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. CREATES Strathmore University (Nairobi City county)
2. Getrudes Childrens Hospital (Nairobi City county)
3. International Cancer Institute (Elgeyo/Marakwet county)
 
30-11-2020 View

336.

ECCT/20/05/02   COPCOV
    Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)   
Principal Investigator(s)
1. Anthony Oliwa Etyang
Site(s) in Kenya
1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county)
2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county)
 
04-09-2020 View

337.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
08-09-2020 View

338.

ECCT/20/04/03   518 & 525-SHAN6â„¢
    Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants.    Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age   
Principal Investigator(s)
1. Bernhards Ogutu
2. Godfrey Allan Otieno
3. Videlis Nduba
4. Lucy Chepkurui Koech
5. samuel Gurrion Ouma
6. Janet Oyieko
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county)
5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county)
6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county)
7. CRDR_Siaya Annex(Back-up site) (Siaya county)
 
11-08-2020 View

339.

ECCT/20/05/03   A5381
    Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment   
Principal Investigator(s)
1. Victor Mudhune
Site(s) in Kenya
Kisumu Clinical Research Center
 
21-08-2020 View

340.

ECCT/20/06/06   E-MOTIVE FORMATIVE
    Understanding effectiveness of implementation of a postpartum haemorrhage initial response bundle   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Mwingi Sub county (level 4 ) hospital (Kitui county)
2. Nyeri Level 5 Hospital (Nyeri county)
3. Garissa county referral hospital (Garissa county)
4. Embu Level 5 hospital (Embu county)
5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county)
6. Meru Teaching and Referral Hospital (Meru county)
7. Kitengela Sub county Hospital (Kajiado county)
8. Kakamega County Government Referral Hospital (Kakamega county)
9. Mbagathi County Hospital (Nairobi City county)
10. St. Mary\'s Mission Hospital (Nairobi City county)
 
15-10-2020 View